Overview

R(+)XK469 in Treating Patients With Advanced Neuroblastoma

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of R(+)XK469 in treating patients with advanced neuroblastoma. Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die.
Phase:
Phase 1
Details
Lead Sponsor:
National Cancer Institute (NCI)